Pandemic (H1N1) 2009 Influenza Update: GSK’s H1N1 ‘Pandemrix’ vaccine receives European Commission Approval, GlaxoSmithKline

Release Date: 2009-09-30

Issued: Wednesday 30 September 2009, London UK
GlaxoSmithKline (GSK) confirmed today that the European Commission has granted marketing authorisation of GSK’s pandemic (H1N1) adjuvanted vaccine Pandemrix™ for protection against pandemic H1N1 2009 influenza.

“Following the Commission’s approval we expect to commence shipments of Pandemrix to European governments from next week,” said Jean Stéphenne, President GlaxoSmithKline Biologicals.

Further information on GSK’s development of a vaccine to protect against pandemic (H1N1) 2009, including explanation of the vaccine development process and background information on adjuvants is available on: http://www.gsk.com/media/pandemic-flu.htm
Type: NORMAL
Company: GlaxoSmithKline
Country: United Kingdom
 
This website requires Flash Player 9 or later. If you can not view this site you probably need to update your system with this plug-in for your browser.